Fisher & Paykel Healthcare Corporation Limited revised earnings guidance for the financial year ending 31 March 2024. The full year guidance previously provided on 29 November 2023, based on a NZ:US exchange rate of 58 cents, was for operating revenue to be approximately $1.7 billion and net profit after tax to be in the range of approximately $250 million to $260 million. Now, assuming a NZ:US exchange rate of approximately 61 cents for the balance of the financial year, the company expects full year operating revenue to be approximately $1.73 billion and underlying profit after tax (excluding any fair value changes) to be in the range of approximately $260 million to $265 million.
Fisher & Paykel Healthcare Corporation Limited
Equities
FPH
NZFAPE0001S2
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.47 NZD | +1.71% | +7.68% | +20.64% |
Apr. 09 | New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask | MT |
Apr. 09 | Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.64% | 9.83B | |
-3.02% | 184B | |
-1.53% | 107B | |
-4.13% | 67.78B | |
+1.31% | 50.66B | |
+12.25% | 47.64B | |
+4.60% | 41.12B | |
+1.86% | 26.3B | |
+2.29% | 26.04B | |
+15.06% | 25.4B |
- Stock Market
- Equities
- FPH Stock
- News Fisher & Paykel Healthcare Corporation Limited
- Fisher & Paykel Healthcare Corporation Limited Revises Earnings Guidance for the Financial Year Ending 31 March 2024